[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer]
- PMID: 11681250
[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer]
Abstract
TS-1, a novel oral formation of 5-fluorouracil, consists of tegafur (5-FU), CDHP and Oxo. Low-dose cisplatin (CDDP) and TS-1 was evaluated in 12 patients with advanced or recurrent gastric cancer. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 80 mg/body of TS-1 was orally administered as many times as possible. The response rate was 41.7%. Median survival time was 13.3 months. In one case, an adverse reaction of grade 3 leucopenia was observed. Thus, thought it is necessary to watch for leucopenia, this chemotherapy could well be effective for patients with advanced or recurrent gastric cancer.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical